Literature DB >> 26001148

Spatial Tumor Heterogeneity in Lung Cancer with Acquired Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor Resistance: Targeting High-Level MET-Amplification and EGFR T790M Mutation Occurring at Different Sites in the Same Patient.

Matthias Scheffler1, Sabine Merkelbach-Bruse, Marc Bos, Jana Fassunke, Masyar Gardizi, Sebastian Michels, Laura Groneck, Anne M Schultheis, Florian Malchers, Frauke Leenders, Carsten Kobe, Katharina König, Lukas C Heukamp, Martin L Sos, Roman K Thomas, Reinhard Büttner, Jürgen Wolf.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26001148     DOI： 10.1097/JTO.0000000000000503

Source DB:  PubMed          Journal:  J Thorac Oncol        ISSN： 1556-0864            Impact factor:   15.609


× No keyword cloud information.
  11 in total

1.  Developments in oncological positron emission tomography/computed tomography assessment.

Authors:  Carsten Kobe; Ronald Boellaard; Jürgen Wolf; Georg Kuhnert; Markus Dietlein; Bernd Neumaier; Alexander Drzezga; Deniz Kahraman
Journal:  J Thorac Dis       Date:  2015-12       Impact factor: 2.895

2.  Deciphering intra-tumor heterogeneity of lung adenocarcinoma confirms that dominant, branching, and private gene mutations occur within individual tumor nodules.

Authors:  Giuseppe Pelosi; Alessio Pellegrinelli; Alessandra Fabbri; Elena Tamborini; Federica Perrone; Giulio Settanni; Adele Busico; Benedetta Picciani; Maria Adele Testi; Lucia Militti; Patrick Maisonneuve; Barbara Valeri; Angelica Sonzogni; Claudia Proto; Marina Garassino; Filippo De Braud; Ugo Pastorino
Journal:  Virchows Arch       Date:  2016-04-07       Impact factor: 4.064

3.  NF-κB-driven suppression of FOXO3a contributes to EGFR mutation-independent gefitinib resistance.

Authors:  Ching-Feng Chiu; Yi-Wen Chang; Kuang-Tai Kuo; Yu-Shiuan Shen; Chien-Ying Liu; Yang-Hao Yu; Ching-Chia Cheng; Kang-Yun Lee; Feng-Chi Chen; Min-Kung Hsu; Tsang-Chih Kuo; Jui-Ti Ma; Jen-Liang Su
Journal:  Proc Natl Acad Sci U S A       Date:  2016-04-18       Impact factor: 11.205

Review 4.  Potentiating Therapeutic Effects of Epidermal Growth Factor Receptor Inhibition in Triple-Negative Breast Cancer.

Authors:  Kyu Sic You; Yong Weon Yi; Jeonghee Cho; Jeong-Soo Park; Yeon-Sun Seong
Journal:  Pharmaceuticals (Basel)       Date:  2021-06-18

Review 5.  Update on recent preclinical and clinical studies of T790M mutant-specific irreversible epidermal growth factor receptor tyrosine kinase inhibitors.

Authors:  Bin-Chi Liao; Chia-Chi Lin; Jih-Hsiang Lee; James Chih-Hsin Yang
Journal:  J Biomed Sci       Date:  2016-12-03       Impact factor: 8.410

6.  SCLLTargeting FGFR1 to suppress leukemogenesis in syndromic and de novo AML in murine models.

Authors:  Qing Wu; Aaron Bhole; Haiyan Qin; Judith Karp; Sami Malek; John K Cowell; Mingqiang Ren
Journal:  Oncotarget       Date:  2016-08-02

7.  Primary Patient-Derived Cancer Cells and Their Potential for Personalized Cancer Patient Care.

Authors:  David P Kodack; Anna F Farago; Anahita Dastur; Matthew A Held; Leila Dardaei; Luc Friboulet; Friedrich von Flotow; Leah J Damon; Dana Lee; Melissa Parks; Richard Dicecca; Max Greenberg; Krystina E Kattermann; Amanda K Riley; Florian J Fintelmann; Coleen Rizzo; Zofia Piotrowska; Alice T Shaw; Justin F Gainor; Lecia V Sequist; Matthew J Niederst; Jeffrey A Engelman; Cyril H Benes
Journal:  Cell Rep       Date:  2017-12-12       Impact factor: 9.423

8.  Dual MET and ERBB inhibition overcomes intratumor plasticity in osimertinib-resistant-advanced non-small-cell lung cancer (NSCLC).

Authors:  A Martinez-Marti; E Felip; J Matito; E Mereu; A Navarro; S Cedrés; N Pardo; A Martinez de Castro; J Remon; J M Miquel; A Guillaumet-Adkins; E Nadal; G Rodriguez-Esteban; O Arqués; R Fasani; P Nuciforo; H Heyn; A Villanueva; H G Palmer; A Vivancos
Journal:  Ann Oncol       Date:  2017-10-01       Impact factor: 32.976

9.  NF-κB-driven improvement of EHD1 contributes to erlotinib resistance in EGFR-mutant lung cancers.

Authors:  Xiaoyuan Wang; Hang Yin; Hongxia Zhang; Jing Hu; Hailing Lu; Chunhong Li; Mengru Cao; Shi Yan; Li Cai
Journal:  Cell Death Dis       Date:  2018-04-01       Impact factor: 8.469

Review 10.  Novel approaches against epidermal growth factor receptor tyrosine kinase inhibitor resistance.

Authors:  Carina Heydt; Sebastian Michels; Kenneth S Thress; Sven Bergner; Jürgen Wolf; Reinhard Buettner
Journal:  Oncotarget       Date:  2018-03-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.